Latest Articles
'I'm a struggling mum and I cried during my PIP assessment and still scored zero points' - Birmingham Live
'I'm a struggling mum and I cried during my PIP assessment and still scored zero points' Birmingham Live
Published: May 10, 2025, 4:30 a.m.
Study Finds Endometriosis May Be Linked to Traumatic Experiences - Pharmacy Times
Study Finds Endometriosis May Be Linked to Traumatic Experiences Pharmacy Times
Published: May 9, 2025, 4:58 p.m.
Country star Kaylee Bell on unexpected motherhood - farmersweekly.co.nz
Country star Kaylee Bell on unexpected motherhood farmersweekly.co.nz
Published: May 9, 2025, 1:29 a.m.
Depo Provera Lawsuit Settlement | May 2025 Update - Lawsuit Information Center
Depo Provera Lawsuit Settlement | May 2025 Update Lawsuit Information Center
Published: May 7, 2025, 2:42 p.m.
TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids - BioSpace
TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids BioSpace
Published: May 7, 2025, 1:28 p.m.
Dr. Karli Provost Goldstein Named to 2025 New York Rising Stars List for Fourth Consecutive Year - PharmiWeb.com
Dr. Karli Provost Goldstein Named to 2025 New York Rising Stars List for Fourth Consecutive Year PharmiWeb.com
Published: May 7, 2025, 12:28 p.m.
TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids - The Manila Times
TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids The Manila Times
Published: May 7, 2025, 12:24 p.m.
TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids - PR Newswire
TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids PR Newswire
Published: May 7, 2025, noon
TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids - 스페셜타임스
TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids 스페셜타임스
Published: May 7, 2025, noon
Daewon Pharm’s uterine fibroid drug meets primary endpoint in P2 trial - koreabiomed.com
Daewon Pharm’s uterine fibroid drug meets primary endpoint in P2 trial koreabiomed.com
Published: May 7, 2025, 6:51 a.m.
Link copied to clipboard!